Table 2.
Raw and Tregitope-adjusted EpiMatrix Score distributions for RA biologics.
| Biologic | Raw EpiMatrix | Tregitope-adjusted EpiMatrix | ||||
|---|---|---|---|---|---|---|
| Median Caucasian | Median Japanese | p-value | Median Caucasian | Median Japanese | p-value | |
| Adalimumab | 62.38 | 61.18 | 1.48E-08 | -20.26 | -19.71 | 0.0027 |
| Certolizumab | 20.22 | 28.05 | 2.71E-18 | -45.28 | -40.73 | 2.71E-18 |
| Golimumab | 8.32 | 10.68 | 3.76E-18 | -38.41 | -30.74 | 2.71E-18 |
| Infliximab | 9.34 | 7.79 | 2.58E-16 | 7.84 | 5.61 | 4.77E-18 |
| Sarilumab | 17.9 | 18.05 | 0.265 | -19.6 | -23.24 | 2.71E-18 |
| Tocilizumab | 41.16 | 32.01 | 2.71E-18 | 12.58 | 4.27 | 2.71E-18 |
| Abatacept | -28.83 | -30.9 | 4.23E-18 | -37.81 | -42.27 | 2.71E-18 |
| Etanercept | -61.26 | -58.66 | 2.71E-18 | -68.01 | -67.29 | 6.80E-15 |
| Lenercept | -44.74 | -46.33 | 2.94E-17 | -52.47 | -56.25 | 2.71E-18 |